Testosterone Undeconate (Nebido, BAY86-5037) + Placebo

ApprovedTerminated
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Hypogonadism

Conditions

Hypogonadism

Trial Timeline

Sep 1, 2010 โ†’ Jul 1, 2011

About Testosterone Undeconate (Nebido, BAY86-5037) + Placebo

Testosterone Undeconate (Nebido, BAY86-5037) + Placebo is a approved stage product being developed by Bayer for Hypogonadism. The current trial status is terminated. This product is registered under clinical trial identifier NCT01092858. Target conditions include Hypogonadism.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01092858ApprovedTerminated